Shopping Cart 0
Cart Subtotal
USD 0

University of California San Diego - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and humanities, biological sciences, physical sciences, engineering, management, international relations and pacific studies, medicine, oceanography, pharmacy and pharmaceutical sciences, and social sciences. It offers more than 100 undergraduate majors in six disciplinary areas; social sciences, engineering, biology, science/math, arts, humanities and special/undeclared. The university provides various courses through six undergraduate colleges, five academic divisions and five graduate and professional schools. It also offers research in the areas of neuroscience, nanoscience and climate science, and provides research funding opportunities. UCSD is headquartered in La Jolla, California, the US.

University of California San Diego-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of California San Diego, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

University of California San Diego, Medical Devices Deals, 2012 to YTD 2018 11

University of California San Diego, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

University of California San Diego, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 15

INSYS Therapeutics Expands Agreement with University of California San Diego 16

Fate Therapeutics Enters into Partnership with University of California San Diego 17

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 18

Biomed Realty Trust Enters into Agreement with University of California San Diego 19

Galmed Pharma Enters into Agreement with University of California 20

Janssen Pharma Enters into Agreement with University of California, San Diego 21

AccentCare Forms Joint Venture With UC San Diego Health System 22

ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 23

Licensing Agreements 24

MonTa Biosciences Enters into Licensing Agreement with University of California and Technical University of Denmark 24

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 25

Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 26

MatriSys Bioscience Enters into Licensing Agreement with University of California, San Diego 27

Oncternal Therapeutics Enters into Licensing Agreement with University of California 28

Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 29

Batu Biologics Enters into Licensing Agreement with University of California, San Diego 30

Curtana Pharma Enters into Licensing Agreement with University of California San Diego 31

SomPharma Enters into Licensing Agreement with University of California, San Diego 32

Abreos Biosciences Enter into License Agreement with University of California San 33

DesignMedix Enters into Licensing Agreement with University of California, San Diego 34

PsychoGenics Enters into Licensing Agreement with University of California, San Diego 35

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 36

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 37

PaxVax Enters into Licensing Agreement with University Of California, San Diego 38

Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 39

Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 40

Equity Offering 41

Antiva Biosciences Spin Out from University of California San Diego 41

University of California San Diego-Key Competitors 42

University of California San Diego-Key Employees 43

University of California San Diego-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Government and Public Interest 46

Sep 20, 2018: Cancer immunotherapy might benefit from previously overlooked immune players 46

Sep 13, 2018: Cancer drug and antidepressants provide clues for treating fatal brain-eating amoeba infections 48

Sep 13, 2018: Caspase-2 enzyme inhibition shows promise for ameliorating fatty liver disease 49

Aug 20, 2018: Bioengineers receive USD 12m grant from NIH to further research on building blocks of human metabolism 51

Jul 05, 2018: Nanofiber-based wound dressings induce production of antimicrobial peptide 53

Apr 10, 2018: Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers 54

Mar 22, 2018: Scientists Create a Noninvasive Wearable System to Monitor Stomach Activity Throughout the Day 56

Feb 16, 2018: New algorithm can pinpoint mutations in large sections of the human genome 58

Feb 06, 2018: Active Genetics Technology Opens New Horizons 59

Dec 20, 2017: NORD Awards Five New Grants for Rare Disease Research 60

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 61

Dec 13, 2017: Electric eel inspires new power source 62

Dec 11, 2017: Scientists discover possible master switch for programming cancer immunotherapy 63

Dec 05, 2017: In Multiple Myeloma, High Levels of Enzyme ADAR1 are Associated with Reduced Survival 65

Dec 01, 2017: State's stem cell agency awards nearly USD 8 million for new leukemia therapies 67

Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 68

Oct 23, 2017: Penn Radiology Researcher Awarded USD 3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 69

Oct 17, 2017: Pair of Discoveries Illuminate New Paths to Flu and Anthrax Treatments 70

Sep 27, 2017: Camino Pharma Co-founder Receives USD 10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 72

Sep 13, 2017: Researchers develop new strategy to target KRAS mutant cancer 73

Sep 13, 2017: NIH UH2 award to develop a new drug for Chagas Disease 74

Sep 07, 2017: Zika virus kills brain cancer stem cells 75

Aug 02, 2017: SAMHSA announces USD 6 million in grants to support the International President's Emergency Plan for AIDS Relief Addiction Technology Transfer Centers 76

Jul 31, 2017: Organovo and UC San Diego Receive USD 1.7 Million Grant From National Institutes of Health to Study Liver Disease 77

May 08, 2017: BrightFocus Foundation Honors Five Researchers on Macular Degeneration and Glaucoma 78

Apr 21, 2017: Using CRISPR to Reverse Retinitis Pigmentosa and Restore Visual Function 79

Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 80

Product News 82

Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 82

Sep 03, 2018: Neutrophil nanosponges soak up proteins that promote rheumatoid arthritis 83

Apr 11, 2017: 'Neuron-reading' nanowires could accelerate development of drugs for neurological diseases 85

Feb 27, 2018: New Online Tool Gives 3D View of Human Metabolic Processes 86

Feb 22, 2018: Artificial intelligence can diagnose and triage retinal diseases 87

Other Significant Developments 88

Jul 23, 2018: UC San Diego bioengineers bring functional genomics data into personal websites 88

Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 89

Appendix 90

Methodology 90

About GlobalData 90

Contact Us 90

Disclaimer 90


List Of Figure

List of Figures

University of California San Diego, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of California San Diego, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

University of California San Diego, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

University of California San Diego, Pharmaceuticals & Healthcare, Key Facts, 2015 2

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of California San Diego, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of California San Diego, Deals By Therapy Area, 2012 to YTD 2018 9

University of California San Diego, Medical Devices Deals, 2012 to YTD 2018 11

University of California San Diego, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 15

INSYS Therapeutics Expands Agreement with University of California San Diego 16

Fate Therapeutics Enters into Partnership with University of California San Diego 17

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 18

Biomed Realty Trust Enters into Agreement with University of California San Diego 19

Galmed Pharma Enters into Agreement with University of California 20

Janssen Pharma Enters into Agreement with University of California, San Diego 21

AccentCare Forms Joint Venture With UC San Diego Health System 22

ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 23

MonTa Biosciences Enters into Licensing Agreement with University of California and Technical University of Denmark 24

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 25

Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 26

MatriSys Bioscience Enters into Licensing Agreement with University of California, San Diego 27

Oncternal Therapeutics Enters into Licensing Agreement with University of California 28

Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 29

Batu Biologics Enters into Licensing Agreement with University of California, San Diego 30

Curtana Pharma Enters into Licensing Agreement with University of California San Diego 31

SomPharma Enters into Licensing Agreement with University of California, San Diego 32

Abreos Biosciences Enter into License Agreement with University of California San 33

DesignMedix Enters into Licensing Agreement with University of California, San Diego 34

PsychoGenics Enters into Licensing Agreement with University of California, San Diego 35

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 36

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 37

PaxVax Enters into Licensing Agreement with University Of California, San Diego 38

Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 39

Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 40

Antiva Biosciences Spin Out from University of California San Diego 41

University of California San Diego, Key Competitors 42

University of California San Diego, Key Employees 43

University of California San Diego, Subsidiaries 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of California San Diego, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.